Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVAGE vs SODIUM TETRADECYL SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
FDA-approved for the topical treatment of stable plaque psoriasis (up to 20% body surface area),FDA-approved for the topical treatment of mild to moderate acne vulgaris,Off-label: treatment of photoaging, facial wrinkles, and certain hyperpigmentation disorders
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins,Treatment of small varicose veins (off-label for larger varicose veins)
Applied topically as a cream 0.05% to affected areas once daily at bedtime.
1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
Tazarotene is rapidly metabolized via ester hydrolysis to its active metabolite, tazarotenic acid. Tazarotenic acid is further metabolized via oxidation and conjugation (glucuronidation). The enzymes involved include esterases and possibly CYP450 isoforms; specific CYP450 enzymes are not well characterized.
Not extensively metabolized; primarily eliminated unchanged by the kidneys.
Primarily renal excretion (70-80% as unchanged drug) with 10-20% biliary/fecal elimination.
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Approximately 90% bound to albumin and alpha-1-acid glycoprotein.
Approximately 50% bound to plasma proteins (albumin and globulins).
0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
0.2–0.3 L/kg, indicating distribution primarily within extracellular fluid and plasma volume.
Oral: 60-70% due to first-pass metabolism; Intravenous: 100%.
Intravenous: 100% (direct intravascular administration). Oral: negligible due to extensive degradation and poor absorption.
No specific dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No specific dose adjustment required for hepatic impairment.
Use with caution in Child-Pugh class C; no specific dose adjustment defined.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
0.1-0.3 m L of 1% solution per injection, repeated as needed; maximum 5 m L per session.
No specific dose adjustment required; however, use with caution due to potential increased sensitivity and skin fragility in elderly patients.
No specific adjustment; use lowest effective dose due to potential increased sensitivity.
Avage is contraindicated in women who are or may become pregnant. Tazarotene is a teratogen, and fetal harm can occur when administered to a pregnant woman. If the drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
None.
Avoid contact with eyes, mouth, and mucous membranes,Not for use on eczematous or sunburned skin,May cause severe local skin reactions (e.g., redness, peeling, burning, stinging),Photosensitivity: patients should avoid or minimize exposure to sunlight and artificial UV sources,Concomitant use with other photosensitizing agents should be approached with caution
Anaphylactic shock and severe allergic reactions have been reported.,Intra-arterial injection can cause severe necrosis or ischemia.,Extravasation may cause pain and tissue necrosis.,Use caution in patients with underlying arterial disease or hypercoagulable states.,Thromboembolic events including deep vein thrombosis and pulmonary embolism have been reported.
Pregnancy (FDA Pregnancy Category X),Women of childbearing potential unless using effective contraception and have a negative pregnancy test within 2 weeks prior to therapy,Hypersensitivity to tazarotene or any component of the formulation
Known hypersensitivity to sodium tetradecyl sulfate or any component of the formulation,Acute thromboembolic disease,Severe peripheral arterial disease,Valvular incompetence of the deep venous system,Uncontrolled systemic disease (e.g., diabetes, thyroid disorders),Local infection or inflammation at the injection site
AVAGE should be taken with a meal containing fat (e.g., whole milk, peanut butter) to enhance absorption. Avoid excessive vitamin A supplements as they may add to toxic effects. Grapefruit juice may increase isotretinoin levels; consider avoidance.
No specific food interactions have been reported with sodium tetradecyl sulfate. However, maintaining adequate hydration is recommended. Avoid excessive alcohol intake, as it may exacerbate venous insufficiency.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Avoid use throughout pregnancy.
Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack of safety data, especially in the first trimester. Theoretical risk of placental transfer is low due to high molecular weight and local administration. No reported fetal anomalies.
Contraindicated in breastfeeding. Excreted into human milk; M/P ratio not established. Risk of serious adverse effects in nursing infant, including keratoderma-like skin changes and potential for growth impairment.
No data on excretion into human milk. M/P ratio unknown. Due to local administration and rapid metabolism, systemic exposure is minimal. Caution advised; consider discontinuing breastfeeding or avoiding use in lactating women.
No dose adjustment applicable; drug is absolutely contraindicated in pregnancy due to teratogenicity. No data on pharmacokinetic changes; theoretical increased clearance due to expanded plasma volume may occur but is clinically irrelevant given contraindication.
No specific dose adjustments recommended. Use only if clearly needed, with smallest effective volume and concentration. Physiological changes in pregnancy (increased plasma volume, altered coagulation) may affect response but no pharmacokinetic data exist.
AVAGE (isotretinoin) is highly teratogenic; confirm negative pregnancy test within 5 days before starting therapy and monthly thereafter. Monitor triglycerides, liver function, and CBC at baseline and monthly. Avoid blood donation during treatment and for 1 month after discontinuation. Use with caution in patients with depression; monitor for mood changes. Administer with food to increase absorption.
Sodium tetradecyl sulfate is a sclerosing agent used for the treatment of varicose veins and telangiectasias. It works by causing endothelial damage and subsequent fibrosis of the vein. Use with caution in patients with a history of deep vein thrombosis, pulmonary embolism, or hypercoagulable states. Allergic reactions, including anaphylaxis, have been reported; a test dose is recommended. Avoid extravasation as it may cause tissue necrosis. Compression stockings should be applied post-injection to enhance efficacy and reduce complications.
AVAGE can cause severe birth defects; females must use two effective forms of contraception and have monthly pregnancy tests.,Do not donate blood while taking AVAGE and for 1 month after stopping.,Avoid exposure to sunlight or tanning beds; use sunscreen and protective clothing.,Report any signs of depression, mood changes, or thoughts of self-harm immediately.,Take each dose with a full meal to ensure proper absorption.,May cause dry skin, lips, eyes; use moisturizers and artificial tears as needed.,Avoid waxing or laser treatments during therapy and for 6 months after.
This medication is injected directly into your varicose veins to cause them to scar and close.,You may experience temporary bruising, pain, or redness at the injection site.,It is normal for the treated veins to feel hard and lumpy for a few weeks after treatment.,You will need to wear compression stockings for several days to weeks as directed by your healthcare provider.,Avoid sun exposure to the treated area until bruising resolves to reduce the risk of hyperpigmentation.,Seek immediate medical attention if you experience signs of an allergic reaction, chest pain, or difficulty breathing.,Do not discontinue prescribed blood thinners unless instructed by your doctor, as the risk of bleeding may be increased.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVAGE vs SODIUM TETRADECYL SULFATE, answered by our medical review team.
AVAGE is a Topical Retinoid that works by Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.. SODIUM TETRADECYL SULFATE is a Sclerosing Agent that works by Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVAGE and SODIUM TETRADECYL SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVAGE is: Applied topically as a cream 0.05% to affected areas once daily at bedtime.. The standard adult dose of SODIUM TETRADECYL SULFATE is: 1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVAGE and SODIUM TETRADECYL SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVAGE is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural t. SODIUM TETRADECYL SULFATE is classified as Category C. Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.